iOnctura Awarded UK’s MHRA Innovation Passport For Entry Into Innovative Licensing And Access Pathway (ILAP)
iOnctura, a clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer, today announces that the innovative medicine designation, the Innovation Passport, has been awarded for roginolisib, for the treatment of metastatic uveal melanoma by the Medicines & Healthcare products Regulatory Agency (MHRA).
